<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mediators Inflamm</journal-id><journal-title>Mediators of Inflammation</journal-title><issn pub-type="ppub">0962-9351</issn><issn pub-type="epub">1466-1861</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18475722</article-id><article-id pub-id-type="pmc">2365786</article-id>
		<article-id pub-id-type="pii">S0962935196000336</article-id>
		<article-id pub-id-type="doi">10.1155/S0962935196000336</article-id>
	<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise</article-title></title-group><contrib-group>
		<contrib contrib-type="author"><name><surname>Croisier</surname><given-names>J-L.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib>
		<contrib contrib-type="author" corresp="yes"><name><surname>Camus</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref></contrib>
		<contrib contrib-type="author"><name><surname>Monfils</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref></contrib>
		<contrib contrib-type="author"><name><surname>Deby-Dupon</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib>
		<contrib contrib-type="author"><name><surname>Fafchamps</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib>
		<contrib contrib-type="author"><name><surname>Venneman</surname><given-names>I.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib>
		<contrib contrib-type="author"><name><surname>Crielaard</surname><given-names>J-M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib>
		<contrib contrib-type="author"><name><surname>Juchm&#x000e8;s-Ferir</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib>
		<contrib contrib-type="author"><name><surname>Lhermerout</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib>
		<contrib contrib-type="author"><name><surname>Lamy</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib>
		<contrib contrib-type="author"><name><surname>Deby</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib>
	</contrib-group>
		<aff id="aff1"><label>1</label>
			<addr-line>Department of Physical Medicine and Rehabilitation</addr-line>
			<addr-line>Institute of Chemistry</addr-line>
			<country>Belgium</country>
		</aff>
		<aff id="aff2"><label>2</label>
			<addr-line>Center for the Biochemistry of Oxygen</addr-line>
			<addr-line>Institute of Chemistry</addr-line>
			<country>Belgium</country>
		</aff>
		<aff id="aff3"><label>3</label>
			<addr-line>Department of Anesthesiology and Intensive Care Medicine</addr-line>
			<addr-line>ISEPK</addr-line>
			<country>Belgium</country>
		</aff>
		<aff id="aff4"><label>4</label>
			<addr-line>Laboratory of Human Applied Physiology</addr-line>
			<addr-line>ISEPK</addr-line>
			<country>Belgium</country>
		</aff>
		<aff id="aff5"><label>5</label>
			<addr-line>Department of Clinical Biology</addr-line>
			<addr-line>CHU</addr-line>
			<addr-line>University of Li&#x000e8;ge</addr-line>
			<addr-line>Sart Tilman</addr-line>
			<addr-line>Li&#x000e8;ge</addr-line>
			<addr-line>B-4000</addr-line>
			<country>Belgium</country>
		</aff>
	<pub-date pub-type="ppub"><month>6</month><year>1996</year></pub-date><volume>5</volume><issue>3</issue><fpage>230</fpage><lpage>234</lpage><permissions><copyright-statement>Copyright &#x000a9; 1996 Hindawi Publishing Corporation.</copyright-statement><copyright-year>1996</copyright-year><copyright-holder>Hindawi Publishing Corporation</copyright-holder><license license-type="open-access" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract>
		<p>To test the hypothesis that delayed onset muscular soreness (DOMS) following intense eccentric muscle contraction could be due to increased production of prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), ten healthy male subjects were studied. Using a double-blind randomized crossover design, each subject performed two isokinetic tests separated by a period of at least 6 weeks: once with placebo, and once with piroxicam (Feldene<sup>&#x000ae;</sup>). They were given one capsule containing either placebo or piroxicam (20 mg) per day for 6 days with initial doses given starting 3 days prior to isokinetic testing. Exercise consisted of eight stages of five maximal contractions of the knee extensor and flexor muscle groups of both legs separated by 1 min rest phases, on a Kin Trex device at 60<sup>&#x000b0;</sup>/s angular velocity. The subjective presence and intensity of DOMS were evaluated using a visual analogue scale immediately after, and 24 and 48 h after each test. The mean plasma concentration of PGE<sub>2</sub> measured at rest and after exercise was significantly lower in the group treated with piroxicam (p &#x0003c; 0.05). However, statistical analysis (two-way <italic>ANOVA</italic> test) revealed that exercise did not cause any significant change of mean plasma PGE<sub>2</sub> over time in either of the two groups. Eccentric work was followed by severe muscle pain in extensor and flexor muscle groups. Maximal soreness was noted 48 h postexercise. Serum creatine kinase activity and the serum concentration of myoglobin increased significantly, and reached peak values 48 h after exercise in both experimental conditions (p &#x0003c; 0.001). By paired <italic>t</italic>-test, it appeared that there were no significant differences in the serum levels of these two markers of muscle damage between the two groups at any time point. We conclude that: (1) oral administration of piroxicam fails to reduce muscle damage and DOMS caused by strenuous eccentric exercise; and (2) the hypothetical role of increased PGE<sub>2</sub> production in eccentric exercise-induced muscle damage, DOMS, and reduced isokinetic performance is not substantiated by the present results.</p>
	</abstract></article-meta></front></article>


